医学
肺癌
癌症研究
配体(生物化学)
恶性肿瘤
癌症
转移
靶向治疗
肿瘤科
内科学
受体
作者
Weichang Yang,Wenjun Wang,Zhouhua Li,Juan Wu,Xiaotian Huang,Jinbo Li,Xinyi Zhang,Xiaoqun Ye
标识
DOI:10.1016/j.critrevonc.2023.104136
摘要
Small cell lung cancer (SCLC) is one of a pathological type of lung cancer, and it is characterized by invasiveness, high malignancy and refractoriness. The mortality rate of SCLC is significantly higher than other types of lung cancer, and the treatment options for SCLC patients are limited. Delta-like ligand 3 (DLL3) is a Notch signaling ligand that plays a role in regulating the proliferation, development and metastasis of SCLC cells. Mnay studies have shown that DLL3 is overexpressed on the surface of SCLC cells, suggesting that DLL3 is a potential target for SCLC patients. A series of drug trials targeting DLL3 are underway. The Phase III clinical trials of Rova-T, a drug targeting DLL3, have not yielded the expected results. However, other drugs that target DLL3, such as AMG119, AMG757 and DLL3-targeted NIR-PIT, bring new ideas for SCLC treatment. Overall, DLL3 remains a valuable target for SCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI